Current promising treatment strategy for glioblastoma multiform: A review

Glioblastoma multiform (GBM) is a heterogeneous group of primary neoplasm resistant to conventional therapies. Due to their infiltrative nature it not fully isolated by aggressive surgery, radiation and chemotherapy showing poor prognosis in glioma patients. Unfortunately, diagnosed patients die wit...

Full description

Saved in:
Bibliographic Details
Published inOncology Reviews Vol. 13; no. 2; p. 417
Main Authors Bahadur, Sanjib, Sahu, Arvind Kumar, Baghel, Pragya, Saha, Suman
Format Journal Article Book Review
LanguageEnglish
Published Switzerland PAGEPress Publications 25.07.2019
PAGEPress Scientific Publications, Pavia, Italy
PAGEPress Publications, Pavia, Italy
Frontiers Media S.A
Subjects
Chemotherapy
Glioblastoma
Medical prognosis
resistance
Review
targeted therapy
temozolomide
temozolomide
targeted therapy
resistance
Glioblastoma
Online AccessGet full text

Cover

Abstract Glioblastoma multiform (GBM) is a heterogeneous group of primary neoplasm resistant to conventional therapies. Due to their infiltrative nature it not fully isolated by aggressive surgery, radiation and chemotherapy showing poor prognosis in glioma patients. Unfortunately, diagnosed patients die within 1.5-2 year treatment schedule. Currently temozolomide (TMZ) is the first choice for the prognosis of GBM patients. TMZ metabolites methyl triazen imidazol carboxamide form complex with alkyl guanine alkyl transferase (O6 MGMT- DNA repair protein) induced DNA damage following resistance properties of TMZ and inhibit the overall survival of the patients. Last few decades different TMZ conjugated strategy is developed to overcome the resistance and enhance the chemotherapy efficacy. The main aim of this review is to introduce the new promising pharmaceutical candidates that significantly influence the therapeutic response of the TMZ in context of targeted therapy of glioblastoma patients. It is hoped that this proposed strategy are highly effective to overcome the current resistance limitations of TMZ in GBM patients and enhance the survival rate of the patients.
AbstractList Glioblastoma multiform (GBM) is a heterogeneous group of primary neoplasm resistant to conventional therapies. Due to their infiltrative nature it not fully isolated by aggressive surgery, radiation and chemotherapy showing poor prognosis in glioma patients. Unfortunately, diagnosed patients die within 1.5-2 year treatment schedule. Currently temozolomide (TMZ) is the first choice for the prognosis of GBM patients. TMZ metabolites methyl triazen imidazol carboxamide form complex with alkyl guanine alkyl transferase (O6 MGMT- DNA repair protein) induced DNA damage following resistance properties of TMZ and inhibit the overall survival of the patients. Last few decades different TMZ conjugated strategy is developed to overcome the resistance and enhance the chemotherapy efficacy. The main aim of this review is to introduce the new promising pharmaceutical candidates that significantly influence the therapeutic response of the TMZ in context of targeted therapy of glioblastoma patients. It is hoped that this proposed strategy are highly effective to overcome the current resistance limitations of TMZ in GBM patients and enhance the survival rate of the patients.
Glioblastoma multiform (GBM) is a heterogeneous group of primary neoplasm resistant to conventional therapies. Due to their infiltrative nature it not fully isolated by aggressive surgery, radiation and chemotherapy showing poor prognosis in glioma patients. Unfortunately, diagnosed patients die within 1.5-2 year treatment schedule. Currently temozolomide (TMZ) is the first choice for the prognosis of GBM patients. TMZ metabolites methyl triazen imidazol carboxamide form complex with alkyl guanine alkyl transferase (O6 MGMT- DNA repair protein) induced DNA damage following resistance properties of TMZ and inhibit the overall survival of the patients. Last few decades different TMZ conjugated strategy is developed to overcome the resistance and enhance the chemotherapy efficacy. The main aim of this review is to introduce the new promising pharmaceutical candidates that significantly influence the therapeutic response of the TMZ in context of targeted therapy of glioblastoma patients. It is hoped that this proposed strategy are highly effective to overcome the current resistance limitations of TMZ in GBM patients and enhance the survival rate of the patients.Glioblastoma multiform (GBM) is a heterogeneous group of primary neoplasm resistant to conventional therapies. Due to their infiltrative nature it not fully isolated by aggressive surgery, radiation and chemotherapy showing poor prognosis in glioma patients. Unfortunately, diagnosed patients die within 1.5-2 year treatment schedule. Currently temozolomide (TMZ) is the first choice for the prognosis of GBM patients. TMZ metabolites methyl triazen imidazol carboxamide form complex with alkyl guanine alkyl transferase (O6 MGMT- DNA repair protein) induced DNA damage following resistance properties of TMZ and inhibit the overall survival of the patients. Last few decades different TMZ conjugated strategy is developed to overcome the resistance and enhance the chemotherapy efficacy. The main aim of this review is to introduce the new promising pharmaceutical candidates that significantly influence the therapeutic response of the TMZ in context of targeted therapy of glioblastoma patients. It is hoped that this proposed strategy are highly effective to overcome the current resistance limitations of TMZ in GBM patients and enhance the survival rate of the patients.
Author Sahu, Arvind Kumar
Baghel, Pragya
Saha, Suman
Bahadur, Sanjib
AuthorAffiliation Department of Pharmaceutics, Columbia Institute of Pharmacy , Near Vidhan Sabha, Raipur, Chhattisgarh, India
AuthorAffiliation_xml – name: Department of Pharmaceutics, Columbia Institute of Pharmacy , Near Vidhan Sabha, Raipur, Chhattisgarh, India
Author_xml – sequence: 1
  givenname: Sanjib
  surname: Bahadur
  fullname: Bahadur, Sanjib
  organization: Department of Pharmaceutics, Columbia Institute of Pharmacy, Near Vidhan Sabha, Raipur, Chhattisgarh, India
– sequence: 2
  givenname: Arvind Kumar
  surname: Sahu
  fullname: Sahu, Arvind Kumar
  organization: Department of Pharmaceutics, Columbia Institute of Pharmacy, Near Vidhan Sabha, Raipur, Chhattisgarh, India
– sequence: 3
  givenname: Pragya
  surname: Baghel
  fullname: Baghel, Pragya
  organization: Department of Pharmaceutics, Columbia Institute of Pharmacy, Near Vidhan Sabha, Raipur, Chhattisgarh, India
– sequence: 4
  givenname: Suman
  surname: Saha
  fullname: Saha, Suman
  organization: Department of Pharmaceutics, Columbia Institute of Pharmacy, Near Vidhan Sabha, Raipur, Chhattisgarh, India
BackLink https://www.ncbi.nlm.nih.gov/pubmed/31410248$$D View this record in MEDLINE/PubMed
BookMark eNqFks1v1DAQxS1URD_gyhFF4sJlt-PPTTggVasWVqrEBc6WY09CVk682E6r_vd4u0vVcuFk6_nNz555PicnU5iQkPcUlgJqehkmG_ySAW2Wgq5ekTParGAhpZInz_an5DylLcAKQMo35JRTQYGJ-oxs1nOMOOVqF8M4pGHqqxzR5HGvpRxNxv6h6kKsej-E1puUw2iqcfZ5KOr4ubqqIt4NeP-WvO6MT_juuF6QnzfXP9bfFrffv27WV7cLKxvICw6KUkCOyEXTWOWYk7alCJ1peYeKtlZJ5QwgNCi4ksJaq4TjzFELvOEXZHPgumC2eheH0cQHHcygH4UQe21iHqxH7VohJFe2RitFB6YxqkZUvNxpnOO2sL4cWLu5HdHZ0nQ0_gX05ck0_NJ9uNNKKSpZXQCXR4DpcRcxpadiCnqfkH5MSO8T0iWhUvHpWBHD7xlT1mXsFr03E4Y5acZWnBW2YMX68R_rNsxxKsPVTDFWA1dKFNfy4LIxpBSx-_8LPjxv-sn-91PwPzUiuvM
CitedBy_id crossref_primary_10_1016_j_lfs_2022_121196
crossref_primary_10_2174_1871527321666220404180944
crossref_primary_10_3390_cells11071173
crossref_primary_10_1016_j_prp_2023_154427
crossref_primary_10_3390_ijms241814069
crossref_primary_10_1088_1742_6596_2058_1_012028
crossref_primary_10_1016_j_bbrc_2020_10_058
crossref_primary_10_1111_jcmm_15114
crossref_primary_10_1007_s12015_020_10011_y
crossref_primary_10_1093_noajnl_vdac019
crossref_primary_10_1016_j_addr_2021_114067
crossref_primary_10_1016_j_isci_2020_101450
crossref_primary_10_1111_jcmm_15192
crossref_primary_10_1093_narcan_zcaa011
crossref_primary_10_1007_s13577_020_00408_9
crossref_primary_10_3389_fonc_2023_1236268
crossref_primary_10_3724_abbs_2023230
crossref_primary_10_1016_j_euroneuro_2020_10_008
crossref_primary_10_3390_cells9122573
crossref_primary_10_1038_s41598_021_99507_2
crossref_primary_10_1109_TUFFC_2023_3320034
crossref_primary_10_3390_antiox10060950
crossref_primary_10_1038_s41419_020_03117_1
crossref_primary_10_3389_fonc_2022_969993
crossref_primary_10_1155_2022_5489553
crossref_primary_10_3389_fchem_2023_1325214
crossref_primary_10_3389_fbioe_2019_00325
crossref_primary_10_1089_ten_tea_2020_0110
crossref_primary_10_2147_CMAR_S258584
crossref_primary_10_3390_ph14111183
crossref_primary_10_3390_cells9081914
crossref_primary_10_2174_2211738510666211222111938
crossref_primary_10_34087_cbusbed_993773
crossref_primary_10_3390_nano14010055
crossref_primary_10_1016_j_ijbiomac_2019_12_158
crossref_primary_10_1111_jcmm_15415
crossref_primary_10_32607_actanaturae_11623
crossref_primary_10_3390_v13091677
crossref_primary_10_3390_cancers12061434
crossref_primary_10_1021_acsabm_3c01219
crossref_primary_10_1093_neuros_nyab124
crossref_primary_10_1097_MD_0000000000035828
crossref_primary_10_3892_ol_2022_13620
crossref_primary_10_1155_2020_3542613
crossref_primary_10_1186_s13287_020_01899_x
crossref_primary_10_1007_s12200_020_1095_y
crossref_primary_10_3389_fncel_2021_709917
crossref_primary_10_1186_s13046_020_01730_8
crossref_primary_10_1007_s12033_022_00632_8
crossref_primary_10_1186_s40478_021_01151_4
crossref_primary_10_3390_ijms25063370
crossref_primary_10_1111_jcmm_16754
crossref_primary_10_1007_s00415_023_11600_w
crossref_primary_10_3390_molecules25245881
crossref_primary_10_1016_j_omto_2020_03_011
crossref_primary_10_1007_s12033_023_00735_w
crossref_primary_10_1007_s12094_021_02732_4
crossref_primary_10_3390_cancers14133116
crossref_primary_10_3390_ijms25115702
crossref_primary_10_1002_biof_1727
crossref_primary_10_1016_j_bbcan_2021_188582
crossref_primary_10_1093_neuonc_noad018
crossref_primary_10_3390_ph14020099
crossref_primary_10_1186_s12645_021_00088_6
crossref_primary_10_3389_fphar_2021_588306
crossref_primary_10_3390_ijms22105105
Cites_doi 10.4314/tjpr.v15i7.19
10.4236/jct.2018.96043
10.3340/jkns.2015.57.5.323
10.1007/s00280-003-0611-2
10.3109/10717544.2015.1038857
10.1586/14737140.6.11.1593
10.1016/j.biopha.2018.12.077
10.3892/ol.2015.3183
10.1016/j.freeradbiomed.2011.10.487
10.1021/acs.molpharmaceut.6b00586
10.1111/j.1755-5949.2012.00319.x
10.3892/etm.2016.3196
10.1134/S1819712416040073
10.1007/s10637-014-0084-7
10.2147/IJN.S37481
10.18632/oncotarget.19875
10.1038/bjc.2013.188
10.1158/0008-5472.CAN-10-3213
10.1215/15228517-2009-007
10.1200/JCO.2008.18.8417
10.1155/2017/9489383
10.1038/srep02534
10.3389/fonc.2012.00098
10.1007/s00280-014-2501-1
10.1634/theoncologist.11-2-152
10.1186/s12935-018-0626-8
10.1016/j.canlet.2014.12.044
10.18632/oncotarget.23855
10.3390/ijms13011109
10.1186/1477-7819-5-89
10.1158/0008-5472.CAN-15-1286
10.1016/j.biomag.2013.08.003
10.1056/NEJMoa1308345
ContentType Journal Article
Book Review
Copyright 2019. This work is published under http://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Copyright: the Author(s), 2019 2019 Licensee PAGEPress, Italy
Copyright_xml – notice: 2019. This work is published under http://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
– notice: Copyright: the Author(s), 2019 2019 Licensee PAGEPress, Italy
DBID NPM
AAYXX
CITATION
ABUWG
AFKRA
AZQEC
BENPR
CCPQU
DWQXO
PIMPY
PQEST
PQQKQ
PQUKI
PRINS
7X8
67V
5PM
DOA
DOI 10.4081/oncol.2019.417
DatabaseName PubMed
CrossRef
ProQuest Central (Alumni Edition)
ProQuest Central UK/Ireland
ProQuest Central Essentials
ProQuest Central
ProQuest One Community College
ProQuest Central Korea
Publicly Available Content Database
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
MEDLINE - Academic
Pagepress
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle PubMed
CrossRef
Publicly Available Content Database
ProQuest Central
ProQuest One Academic UKI Edition
ProQuest Central Essentials
ProQuest Central Korea
ProQuest One Academic Eastern Edition
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest One Academic
ProQuest Central China
MEDLINE - Academic
DatabaseTitleList

Publicly Available Content Database
CrossRef

PubMed
MEDLINE - Academic
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: BENPR
  name: AUTh Library subscriptions: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1970-5565
1970-5557
ExternalDocumentID oai_doaj_org_article_db44536c8ec54f0a9a68ee63d2dadd3c
10_4081_oncol_2019_417
31410248
Genre Journal Article
Review
GroupedDBID ---
-5E
-5G
-BR
.86
123
29N
4.4
53G
5VS
67V
67Z
6NX
8TC
9T4
ABDBF
ADBBV
ADINQ
AFBBN
AFKRA
AHBYD
ALMA_UNASSIGNED_HOLDINGS
AOIJS
BA0
BCNDV
BENPR
CAG
CCPQU
CS3
EBD
EBS
GROUPED_DOAJ
GXS
HG5
HG6
HYE
IZQ
I~X
KPH
KQ8
M48
N9A
NPM
O9I
OAM
OK1
PGMZT
PIMPY
QOS
R9I
RNS
RPM
RPX
RSV
S27
SDH
SMD
SOJ
T13
TSK
U2A
WJK
WK8
AAYXX
CITATION
ABUWG
AZQEC
DWQXO
PQEST
PQQKQ
PQUKI
PRINS
7X8
-
5E
5G
AAPBV
ADACO
BR
COF
5PM
ID FETCH-LOGICAL-c590t-306110e3ee3499c6d2d5cb1e0fab3fe61bc656da0e09e43654ccc64d32d1c0393
IEDL.DBID RPM
ISSN 1970-5565
1970-5557
IngestDate Tue Oct 22 15:15:08 EDT 2024
Tue Sep 17 21:24:26 EDT 2024
Mon Jan 18 12:38:06 EST 2021
Sat Oct 26 04:41:30 EDT 2024
Thu Oct 10 18:47:35 EDT 2024
Fri Aug 23 01:28:50 EDT 2024
Sat Nov 02 12:27:12 EDT 2024
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 2
Keywords temozolomide
targeted therapy
resistance
Glioblastoma
Language English
License This work is licensed under a Creative Commons Attribution NonCommercial 4.0 License (CC BY-NC 4.0).
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c590t-306110e3ee3499c6d2d5cb1e0fab3fe61bc656da0e09e43654ccc64d32d1c0393
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Contributions: the authors contributed equally.
Conflicts of interest: the authors declare no potential conflicts of interest.
OpenAccessLink https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6661528/
PMID 31410248
PQID 2622803664
PQPubID 5316520
ParticipantIDs doaj_primary_oai_doaj_org_article_db44536c8ec54f0a9a68ee63d2dadd3c
pubmedcentral_primary_oai_pubmedcentral_nih_gov_6661528
pagepress_primary_10_4081_oncol_2019_417
proquest_miscellaneous_2273215242
proquest_journals_2622803664
crossref_primary_10_4081_oncol_2019_417
pubmed_primary_31410248
ProviderPackageCode 67V
PublicationCentury 2000
PublicationDate 20190725
PublicationDateYYYYMMDD 2019-07-25
PublicationDate_xml – month: 7
  year: 2019
  text: 20190725
  day: 25
PublicationDecade 2010
PublicationPlace Switzerland
PublicationPlace_xml – name: Switzerland
– name: Bari
PublicationTitle Oncology Reviews
PublicationTitleAlternate Oncol Rev
PublicationYear 2019
Publisher PAGEPress Publications
PAGEPress Scientific Publications, Pavia, Italy
PAGEPress Publications, Pavia, Italy
Frontiers Media S.A
Publisher_xml – name: PAGEPress Publications
– name: PAGEPress Scientific Publications, Pavia, Italy
– name: PAGEPress Publications, Pavia, Italy
– name: Frontiers Media S.A
References 5540
5541
5520
5521
5519
5511
5533
5512
5534
5513
5535
5514
5536
5515
5537
5516
5538
5517
5539
5518
5530
5531
5510
5532
5508
5509
5522
5501
5523
5502
5524
5503
5525
5504
5526
5505
5527
5506
5528
5507
5529
References_xml – ident: 5522
– ident: 5536
  doi: 10.4314/tjpr.v15i7.19
– ident: 5518
  doi: 10.4236/jct.2018.96043
– ident: 5524
– ident: 5511
  doi: 10.3340/jkns.2015.57.5.323
– ident: 5513
  doi: 10.1007/s00280-003-0611-2
– ident: 5529
  doi: 10.3109/10717544.2015.1038857
– ident: 5538
– ident: 5501
  doi: 10.1586/14737140.6.11.1593
– ident: 5527
  doi: 10.1016/j.biopha.2018.12.077
– ident: 5515
  doi: 10.3892/ol.2015.3183
– ident: 5528
  doi: 10.1016/j.freeradbiomed.2011.10.487
– ident: 5534
  doi: 10.1021/acs.molpharmaceut.6b00586
– ident: 5505
  doi: 10.1111/j.1755-5949.2012.00319.x
– ident: 5523
– ident: 5520
  doi: 10.3892/etm.2016.3196
– ident: 5509
  doi: 10.1134/S1819712416040073
– ident: 5531
  doi: 10.1007/s10637-014-0084-7
– ident: 5539
  doi: 10.2147/IJN.S37481
– ident: 5521
  doi: 10.18632/oncotarget.19875
– ident: 5526
  doi: 10.1038/bjc.2013.188
– ident: 5530
  doi: 10.1158/0008-5472.CAN-10-3213
– ident: 5506
  doi: 10.1215/15228517-2009-007
– ident: 5507
  doi: 10.1200/JCO.2008.18.8417
– ident: 5525
  doi: 10.1155/2017/9489383
– ident: 5541
  doi: 10.1038/srep02534
– ident: 5503
  doi: 10.3389/fonc.2012.00098
– ident: 5512
  doi: 10.1007/s00280-014-2501-1
– ident: 5502
  doi: 10.1634/theoncologist.11-2-152
– ident: 5510
  doi: 10.1186/s12935-018-0626-8
– ident: 5514
– ident: 5504
  doi: 10.1016/j.canlet.2014.12.044
– ident: 5519
  doi: 10.18632/oncotarget.23855
– ident: 5535
  doi: 10.3390/ijms13011109
– ident: 5537
– ident: 5516
  doi: 10.1186/1477-7819-5-89
– ident: 5508
– ident: 5533
– ident: 5532
  doi: 10.1158/0008-5472.CAN-15-1286
– ident: 5540
  doi: 10.1016/j.biomag.2013.08.003
– ident: 5517
  doi: 10.1056/NEJMoa1308345
SSID ssj0070055
Score 2.4465246
Snippet Glioblastoma multiform (GBM) is a heterogeneous group of primary neoplasm resistant to conventional therapies. Due to their infiltrative nature it not fully...
SourceID doaj
pubmedcentral
pagepress
proquest
crossref
pubmed
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
StartPage 417
SubjectTerms Chemotherapy
Glioblastoma
Medical prognosis
resistance
Review
targeted therapy
temozolomide
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3LbtUwEB2hLngsEG8CBRkJCTahTvzIDbuCqApSWVGpO8uPCVQqCaK3C_6eGTs39CKkbtgmkZ2cE2fOxONjgJdxoCQZvayx8ZSgpK6pveywHtqkgjbJJ8kLhY8-28Nj_enEnFza6otrwoo9cAFuLwWtjbJxhdHoQfre2xWiVamldpKK-esr-00yVb7BHVtL5fnkTtbGmK7YNWqKf3vTSAhzTVf_Rudtyv6Eo-zafwtu8FDOZaj_kp1_V09eCkcHd-D2rCPFfrn_u3ANx3tw_WieKb8PH2fjJUEtE5UUoMRSUy7OiyXtL0GKVXw9O50Caej19N2LXF_IOvat2BdlWcsDOD748OX9YT1vm1BH08t1TUkAxXRUiIrSmWgJKRNDg3LwQQ1omxBJxCUvUfaolTU6xmh1Um1qIi_VfQg74zTiYxBJqkiKzLZdEzRq67EnOnwYGu-Vj6GCVxv03I_ijuEoq2CcXcbZMc6OcK7gHYO7XMWu1vkAce1mrt1VXFfweqHmyv52N8y5eVSeu9ay-Y-yVlfwYjlNJPAkiR9xuqBrSM_xXr-6reBRIXrpSnFRbKtXFXRbr8DWU22fGU-_Zc9uyhKp0dWT_wHDU7jJj8l_mFuzCzvrnxf4jKTROjzPo-A3kPMPuA
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: ProQuest Central
  dbid: BENPR
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwhV1Lb9QwEB7BVoL2xLuBgoyEBJdQx69suCCKWhWkVghRqbfIj0mpBEnpbg_8e2aSbMoiBNfYsuMZex72zDcAL2JDTjJ6mWPhyUFJZZF7WWLeqKSDscknyYnCR8fu8MR8PLWn44XbYgyrXMnEXlCnLvId-a5yDNyinTNvL37kXDWKX1fHEho3YUORp6BmsLG3f_zp80oWlwwx1b8rlzK31pYDbKMhPbjbtURpju2qXpu-XNm1WurR-7fgNh_pPhz1b-bnn1GUv6mlgzuwxakKYrjfvws3sL0Ht47G1_L78GEEXxI0KrGTlJSY4srFYoCl_SnIahVn3867QHb0svvuRR9jyLbsG_FODKktD-DkYP_L-8N8LJ2QR1vJZU6OAOl11IiaXJrokko2hgJl44Nu0BUhkiGXvERZodHOmhijM0mrVERO130Is7ZrcRtEkjqSVeZUWQSDxnmsgjE-NIX32seQwcsV5eqLASGjJs-CaVz3NK6ZxjXROIM9JuzUi5Gt-w_d5Vk9HpQ60eBWuzjHaE0jfeXdHNFpWgGJYh0zeDWx5b_z7ay4Vo8nc1Ff76MMnk_NxAR-KPEtdlfUh2w6rvdrVAaPBiZPU2kOjFVmnkG5xv61Va23tOdfe9xu8hRp0Pnjf__WE9jkBfD9sbI7MFteXuFTMnyW4dm4u38Baj8FTA
  priority: 102
  providerName: ProQuest
– databaseName: Scholars Portal Journals: Open Access
  dbid: M48
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3da9RAEB-0gh8P4rfRKisI-pLrJvuRiy9SxVKF-uRB35b9mNRCTfR6BfvfO5PkoicH-haymw07M5v5TWb2twAvY0NBMnqZY-EpQElVkXtZYd6USQVtkk-SNwoffbaHC_3p2Bz_rn8aBXi-NbTj86QWy7PZzx-Xb2nBE36dafJoe11LMuMqrXqmi-oqXCuZlIvL-PSUUaiYbKrPMFcyN8ZUA4Hjluc3HFTP438LbvDi7gtTtwHRv-sp_3BQB3fg9ogsxf5gCnfhCrb34PrRmDu_Dx9HKiZBI5NyyWWJqcpcnA8ktZeCMKw4OTvtAqHqVffNi77ikJHtG7Evho0uD2Bx8OHL-8N8PEghj6aWq5zCAvLyqBAVBTjRpjKZGAqUjQ-qQVuESLAueYmyRq2s0TFGq5MqUxF58-5D2Gm7Fh-DSFJFwmi2rIqgUVuPddDah6bwXvkYMni1lp77PvBlOIozWM6ul7NjOTuScwbvWLhTL-a57m90yxM3LhuXaHCjbJxjNLqRvvZ2jmgVzYA-zCpm8HpSzT_ft7vWnFubmSst0wEpa3UGL6ZmUgKnTXyL3QX1IYTHp__qMoNHg6KnVykuky31PINqwwQ2ZrXZ0p5-7Vm8KW6kQedP_n8GT-EmX_Kf5dLsws5qeYHPCBKtwvPe1n8Bh4UM5A
  priority: 102
  providerName: Scholars Portal
Title Current promising treatment strategy for glioblastoma multiform: A review
URI https://www.ncbi.nlm.nih.gov/pubmed/31410248
https://www.proquest.com/docview/2622803664
https://www.proquest.com/docview/2273215242
http://dx.doi.org/10.4081/oncol.2019.417
https://pubmed.ncbi.nlm.nih.gov/PMC6661528
https://doaj.org/article/db44536c8ec54f0a9a68ee63d2dadd3c
Volume 13
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1La9wwEB6SFPo4lL7rNl1UKLQX78rWw-vekpCQFjaE0kBuRo9xspC1Q7I59N93JD_IlkKhFx_81szI84316RPAJ1dTkYyGp5gZKlB8kaWGF5jWuRdWKm88DxOFFyf6-Ex-P1fnW6CGuTCRtO_sctpcrabN8jJyK69XbjbwxGaniwOC3JR25rNt2KYAHUr07vNbBFWpOJRc8FQRXOmUGiWlvlnbkHEDnaucyiwsvycCyzEPa__cS0pRu_8JPAodOpJR_wY-_-RQ3ktKR8_gaY8m2V731s9hC5sX8HDRj5e_hG-9_BKjO5NDKU2xkVnObjth2l-McCu7uFq2lpD0ul0ZFlmGAc1-ZXusm9zyCs6ODn8eHKf94gmpUyVfp1QKUGZHgSioqHHa5145myGvjRU16sw6gnLecOQlSqGVdM5p6UXuMxcm7L6GnaZt8C0wz4UjXKbzIrMSpTZYWimNrTNjhHE2gc-D9arrTiOjotoimLyKJq-CySsyeQL7wbjjWUHbOu5oby6q3sOVp5srod0cnZI1N6XRc0QtqAX0MRYugS-ja_75vN3Bc1XfN2-rXAcJIKG1TODjeJicEIZKTIPtHZ1DqC6s-CvzBN50jh4fNQRNAsVGCGy0avMIBXJU7u4D991_X_keHoe2hZ_LudqFnfXNHX4gVLS2E3iwf3hy-mMS_yrQdiHnk9gzfgP_jRHy
link.rule.ids 230,314,315,730,783,787,795,867,888,2109,2228,21402,24332,27936,27938,27939,33758,33759,43819,53806,53808,74638
linkProvider National Library of Medicine
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwhV3dT9RAEJ8oJAJPfmIRdU1M9KWy7X706gsBAzmUuxgDCW-b_SqSYIvc8cB_70zbK54x-trd7HZndudjd-Y3AG99hU5ytDyNmUUHJRRZankR0yoPwkkVbOCUKDyZ6vGp_HymzvoLt1kfVrmQia2gDo2nO_KdXBNwi9Ba7l79TKlqFL2u9iU07sMqQVXhrl7dP5h-_baQxQVBTLXvygVPlVJFB9soUQ_uNDVSmmK7yg-yLVd2p5Za9P4NWKMj3Yaj_s38_DOK8je1dPgQNihVgXX3-4_gXqwfw4NJ_1r-BI568CWGoyI7UUmxIa6czTpY2luGVis7v7xoHNrR8-aHZW2MIdmyH9ke61JbnsLp4cHJp3Hal05IvSr5PEVHAPV6FDEKdGm8DnlQ3mWRV9aJKurMeTTkguWRl1EKraT3Xssg8pB5Std9Bit1U8fnwAIXHq0ynReZk1FqG0snpXVVZq2w3iXwbkE5c9UhZBj0LIjGpqWxIRobpHEC-0TYoRchW7cfmutz0x8UE3BwJbQfRa9kxW1p9ShGLXAFKIqFT-D9wJb_zre94JrpT-bM3O2jBN4MzcgEeiixdWxusA_adFTvV-YJbHZMHqYSFBiby1ECxRL7l1a13FJffG9xu9FTxEFHW__-rdewNj6ZHJvjo-mXF7BOi6G75Fxtw8r8-ia-RCNo7l71O_0X9-gIRg
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwhV1Lb9QwEB7BVir0xLMEChgJCS5hnfiRDRdEoasW6KpCVOrN8iulEiSluz3w75lJvFsWIbjGlh3P2J4Z-_M3AM99g0FytDyPhcUAJVRFbnkV86YMwkkVbOD0UPhwpveP5YcTdZLwT_MEq1zuif1GHTpPZ-TjUhNxi9BajpsEizh6P31z_iOnDFJ005rSaVyHjUrirBrBxu7e7Ojzcl-uiG6qv2OueK6UqgYKR4k2cdy1KHXCedWvZJ-67MpE9Uz-W3CDlncPTf2bK_onovI3EzW9BVv0bIENZ_234Vps78DmYbo5vwsHiYiJYauoWjRYbIUxZ_OBovYnQw-WnX476xz61Ivuu2U93pD82tfsLRueudyD4-nel3f7eUqjkHtV80WOQQHa-ChiFBjeeB3KoLwrIm-sE03UhfPo1AXLI6-jFFpJ772WQZSh8PR09z6M2q6ND4AFLjx6aLqsCiej1DbWTkrrmsJaYb3L4MVScuZ8YMswGGWQjE0vY0MyNijjDHZJsKtaxHLdf-guTk1aNCZg40poP4leyYbb2upJjFrgCHBbFj6Dlyu1_Le_naXWTFqlc3M1pzJ4tipGJdCliW1jd4l10L-j3L-yzGB7UPKqK0Eg2VJOMqjW1L82qvWS9uxrz-GNUSM2Onn47996Cps4yc2ng9nHR3CTxkLHyqXagdHi4jI-Rn9o4Z6kif4LQa0Meg
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Current+promising+treatment+strategy+for+glioblastoma+multiform%3A+A+review&rft.jtitle=Oncology+Reviews&rft.au=Bahadur%2C+Sanjib&rft.au=Sahu%2C+Arvind+Kumar&rft.au=Baghel%2C+Pragya&rft.au=Saha%2C+Suman&rft.date=2019-07-25&rft.pub=PAGEPress+Publications&rft.issn=1970-5557&rft.eissn=1970-5565&rft.volume=13&rft.issue=2&rft_id=info:doi/10.4081%2Foncol.2019.417&rft.externalDBID=HAS_PDF_LINK
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1970-5565&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1970-5565&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1970-5565&client=summon